Nitric Oxide Nasal Spray Trial for Sinusitis Treatment

A Vancouver-based company, SaNOtize Research & Development Corp., has initiated a Phase 2 clinical trial for a new Nitric Oxide Nasal Spray (NONS) designed to address recurrent acute rhinosinusitis (RARS). The trial involves 186 participants in Canada and aims to compare the spray's safety and effectiveness against a placebo.

The study's primary objective is to assess whether NONS can expedite the recovery process from sinusitis episodes and alleviate symptoms more rapidly than conventional treatments. It also seeks to determine the spray's potential to reduce the reliance on antibiotics and steroids for RARS patients.

SaNOtize's NONS has previously shown promising results in clinical trials for COVID-19, where it was found to shorten the illness duration and decrease viral loads in patients. The company is now looking to leverage its nitric oxide technology to combat a broader spectrum of upper respiratory infections.

The Nitric Oxide Releasing Solution (NORS™) platform, which underpins the NONS, represents an innovative approach to treating various upper respiratory infections. Steve Basta, CEO of SaNOtize, expressed his optimism about the potential of their nasal spray to offer a novel treatment option for sinusitis, harnessing the antimicrobial properties of nitric oxide.

SaNOtize specializes in the development and commercialization of antimicrobial products that release nitric oxide. Their patented NORS™ technology is intended for treating and preventing both upper respiratory and topical infections.